Discover your health risks by analysing your DNA.
DNA Risk: HLA - R2850
About This Test:
The comprehensive DNA Risk HLA-Related Autoimmunity (HLA test) looks at gene variants related to common autoimmune diseases and provides healthcare practitioners ‘diagnostic insight’ for patients already suffering from an autoimmune disorder, or who are identified as at risk due to a family history of disease and exposure to environmental risk factors.
The DNA Risk HLA-Related Autoimmunity test is suitable for individuals suffering from an autoimmune disorder, or where an autoimmune disorder is suspected. Individuals identified as being at risk due to a family history of disease and/or exposure to environmental risk factors should also consider this test.
The report presents the HLA alleles and genotype data in a user-friendly manner, followed by a brief description of the relevant autoimmune disorders, insights into environmental contributors, and risk (and protective) HLA alleles and MHC-related gene variants related to the disorders.
- Alopecia areata (AA)
- Ankylosing spondylitis (AS)
- Coeliac disease (CD)
- Graves’ disease (GD)
- Hashimoto thyroiditis (HT)
- IgA nephropathy (IgAN)
- Lyme borreliosis
- Multiple sclerosis (MS)
- Rheumatoid arthritis (RA)
- Systemic lupus erythematosus (SLE)
- Idiopathic membranous nephropathy (IMN)
TruCheck - R11 845 - R22 195
Standard screening programs are effective for some but not all cancer types and in general are far more complex and resource-intensive than early diagnosis as they require special equipment and dedicated personnel. Performing Cancer screening tests regularly may find breast, cervical, and colorectal (colon) cancers early, when treatment is likely to work best.
Trucheck™ is a blood test that can enable early detection of multiple cancers in asymptomatic individuals. Trucheck is intended to be performed annually as a routine test.
Why should I considder Trucheck?
- Circulating Tumor Cells (CTCs) and their clusters are present in the blood of almost all cancer patients and are undetectable even in seemingly healthy individuals.
- Trucheck™ technology to detect and characterize CTCs has been proven through extensive clinical validations involving more than 40,000 participants.
- The test is performed at the world-class Datar Cancer Genetics laboratory, which meets and exceeds all national and international standards.
Trucheck Cancer Screening Tests
Trucheck Breast – R11 845
Trucheck™ is a blood test that can enable early detection of Breast Cancer in asymptomatic individuals.
Trucheck Prostate – R11 845
Trucheck™ is a blood test that can enable early detection of Prostate Cancer in asymptomatic individuals.
Trucheck Diabetes Associated Cancers – R16 583
Trucheck™ is a blood test that can enable early detection of Diabetes Associated Cancers in asymptomatic individuals.
Individuals with Type 2 Diabetes are twice as likely to be diagnosed with liver or pancreatic cancers as compared to those without Type 2 Diabetes. These individuals are also at higher risk of other cancers such as those of the gallbladder, kidney, bladder and colorectum.
Trucheck™ DM is intended to be used for the detection of cancers of the Liver, Gallbladder, Pancreas, Kidney, Bladder and Colorectum, in individuals recently diagnosed, or with existing, Type 2 Diabetes.
Trucheck Intelli – R22 195
Trucheck™ is a blood test that can enable early detection of 70+ Cancer types in asymptomatic individuals.
Melanoma, Head and Neck, Salivary Gland, Thyroid, Lung, Breast, Liver, Biliary Tract, Gastro-Intestinal, Soft Tissue and Osteosarcomas, Mesothelioma, Urinary Tract, Gynecological, Male Cancers including Prostate, CNS, Thymus, Adrenal, Skin.